ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "risk assessment"

  • Abstract Number: 2418 • ACR Convergence 2024

    Identification of Co-expressed Molecular Markers That Predict Risk of Severe Flare in Patients with Systemic Lupus Erythematosus (SLE)

    Matthew Linnik1, Guilherme Rocha2, David Gemperline3, Ernst Dow3, Christoph Preuss3, Helen Masson4, Olivia Ellis4, Ana Accioly3, Maja Hojnik5, Kira Rubtsova1, Robert Benschop6, Mark Chambers7, Mark Genovese3 and Richard Higgs3, 1Eli Lilly, San Diego, CA, 2Eli Lilly, Indianapolis, IN, 3Eli Lilly and Co, Indianapolis, IN, 4Eli Lilly and Co, San Diego, CA, 5Eli Lilly and Co., Indianapolis, IN, 6Eli Lilly and Company, Indianapolis, IN, 7Eli Lilly, Zionsville, IN

    Background/Purpose: SLE flare is a clinically and regulatory relevant outcome, yet limited markers currently exist that predict its risk. We used baseline whole blood/serum samples…
  • Abstract Number: 0209 • ACR Convergence 2024

    Characteristics of Ordering Providers and Patients with Positive Antinuclear Antibodies: A Pragmatic, Risk Model Study

    Emily Grace, Sarah Green, Nikol Nikolova, Ashley Suh, Ryan Moore, Hank Domenico, Allison McCoy and April Barnado, Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Positive antinuclear antibodies (ANAs) cause diagnostic dilemmas for clinicians across specialties. We previously developed and validated a risk model to predict risk of developing…
  • Abstract Number: 0851 • ACR Convergence 2024

    Diagnostic Ultrasound Enthesitis Tool (DUET) for Psoriatic Arthritis: The Distribution of Elementary Lesions Is Influenced by Site

    Lihi Eder1, Ricardo Acayaba de Toledo2, Fahmeen Afgani3, Catherine Bakewell4, Philippe Carron5, Basant Elnady6, Amir Haddad7, Arthur Kavanaugh8, Arnon Katz9, Minna Kohler10, josefina marin11, NZEUSSEU TOUKAP Adrien12, Marcos Rosemffet13, Ari Polachek14, Ernesto Rodriguez15, Ágnes Sarolta Szentpétery16, Abha Singh17, Maria S. Stoenoiu18, Ilaria Tinazzi19, Janeth Yinh10, Gurjit Kaeley20 and Sibel Aydin21, 1University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada, 2FAMERP, São José do Rio Preto, Brazil, 3Women's College Hospital, Toronto, Canada, 4Intermountain Health Care, Salt Lake City, UT, 5UZ Gent, Gent, Belgium, 6Al Hada Forces Hospital, Rheumatology Department, Taif, Saudi Arabia, 7Carmel Medical Centre, Haifa, Israel, 8University of California San Diego, La Jolla, CA, 9GRAPPA - Patient Research Partner, Haifa, Israel, 10Massachusetts General Hospital, Boston, MA, 11Hospital Italiano de Buenos Aires, buenos aires, Argentina, 12Institut de Recherche Expérimentale et Clinique, Cliniques universitaires Saint-Luc, Université catholique de Louvain, St.-Lambrechts-Woluwe, Belgium, 13Instituto de Rehabilitación Psicofísica, Capital Federal, Argentina, 14Tel-Aviv Medical Center, Tel-Aviv, Israel, Petah-Tikva, Israel, 15Florida Medical Clinic, Tampa, FL, 16Uppsala University Hospital, Uppsala, Sweden, 17University of California, San Diego, San Diego, CA, 18Cliniques Universitaires Saint-Luc, Brussels, Belgium, 19Ospedale Sacro Cuore-Don Calabria, Verona, Italy, 20UF COM-J, Ponte Vedra Beach, FL, 21University of Ottawa - Ottawa, Ottawa, ON, Canada

    Background/Purpose: Enthesitis is a key domain in psoriatic arthritis (PsA). The Diagnostic Ultrasound Enthesitis Tool (DUET) study aims to develop a new PsA-specific sonographic scoring…
  • Abstract Number: 1724 • ACR Convergence 2024

    Performance of a Novel Cardiovascular Risk Calculator in Rheumatoid Arthritis

    Tate Johnson1, Halie Frideres2, Punyasha Roul3, Yangyuna Yang1, Joshua Baker4, Sauer brian5, grant Cannon6, Ted Mikuls1 and Bryant England1, 1University of Nebraska Medical Center, Omaha, NE, 2UNMC Department of Rheumatology, Omaha, NE, 3UNMC, Omaha, NE, 4University of Pennsylvania, Philadelphia, PA, 5Salt Lake City VA/University of Utah, Salt Lake City, UT, 6University of Utah and Salt Lake City VA, Salt Lake City, UT

    Background/Purpose: Existing cardiovascular disease (CVD) risk calculators have inadequately estimated CVD risk in people with rheumatoid arthritis (RA). The American Heart Association (AHA) recently developed…
  • Abstract Number: 2444 • ACR Convergence 2024

    Performance of the DETECT Algorithm and Cluster Analysis in Screening for Systemic Sclerosis Pulmonary Hypertension Groups

    Ryan Osgueritchian1, Hoda Mombeini1, Vivek Jani2, Adrianne Woods3, Steven Hsu1, Matthew Lammi4, Paul Hassoun4, Fredrick Wigley5, Laura Hummers6, Stephen Mathai7, Ami Shah8 and Monica Mukherjee1, 1Johns Hopkins University Division of Cardiology, Baltimore, MD, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3Johns Hopkins University Division of Rheumatology, Baltimore, MD, 4Johns Hopkins University Division of Pulmonary and Critical Care Medicine, Baltimore, MD, 5Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Baltimore, MD, 6Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, 7Johns Hopkins University Division of Pulmonary and Critical Care Medicine,, Blatimore, 8Division of Rheumatology, Johns Hopkins University, Ellicott City, MD

    Background/Purpose: Pulmonary hypertension (PH) portends poor outcomes in Systemic Sclerosis (SSc). Recent efforts for early identification and intervention in SSc patients with pulmonary arterial hypertension…
  • Abstract Number: 0293 • ACR Convergence 2024

    Assessment of Skin Cancer Risk in Autoimmune Diseases: A Multivariate Analysis Using a National Inpatient Database

    Sami Rabah and Xiangyi Kang, Lincoln Medical Center, New York, NY

    Background/Purpose: Autoimmune diseases are known to be associated with an increased risk of many types of cancers. This study investigates the association between different types…
  • Abstract Number: 0859 • ACR Convergence 2024

    Incidence of Aortic Aneurysm, Dissection, or Rupture Among Patients with Polymyalgia Rheumatica and Giant Cell Arteritis

    Kylie Carlson1, Mahmut Kaymakci2, Sebastian E. Sattui3 and Michael Putman4, 1Medical College of Wisconsin, Milwaukee, WI, 2Mayo Clinic, Rochester, MN, 3University of Pittsburgh, Pittsburgh, PA, 4The Medical College of Wisconsin, Milwaukee, WI

    Background/Purpose: Patients with polymyalgia rheumatica (PMR) may develop overt giant cell arteritis (GCA), but “subclinical” large vessel inflammation has also been reported in patients with…
  • Abstract Number: 1725 • ACR Convergence 2024

    Exploring Risks of Polymyalgia Rheumatica (PMR), Giant Cell Arteritis (GCA) and Complications While Receiving Immune Checkpoint Inhibitors: Comparative Analysis

    Irakli Tskhakaia and Arthur Lau, Jefferson Einstein Hospital, Philadelphia, PA

    Background/Purpose: Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, offering significant benefits in various malignancies. However, these therapies can induce immune-related adverse events (irAEs), including…
  • Abstract Number: 2469 • ACR Convergence 2024

    Machine Learning Identifies Oesophageal Symptoms as a New Red Flag for for Very Early Diagnosis of Systemic Sclerosis (VEDOSS): A EUSTAR Analysis

    Stefano Di Donato1, Vishal Kakkar2, Silvia Bellando-Randone3, Marco Matucci-Cerinic4 and Francesco Del Galdo2, and EUSTAR collaborators, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, 2University of Leeds, Leeds, United Kingdom, 3University of Florence, Florence, Florence, Italy, 4University San Raffaele Milano, Milano, Milan, Italy

    Background/Purpose: The analysis of the EUSTAR Very Early Diagnosis of Systemic Sclerosis (VEDOSS) study has identified the risk of progression to fulfil 2013 ACR/EULAR classification…
  • Abstract Number: 0294 • ACR Convergence 2024

    Obesity and Risk of Autoimmune Diseases: Insights from the National Inpatient Sample

    Sami Rabah and Xiangyi Kang, Lincoln Medical Center, New York, NY

    Background/Purpose: Obesity has been implicated as a risk factor in developing various cardiovascular, respiratory, and other health complications. However, the link between obesity and autoimmune…
  • Abstract Number: 1000 • ACR Convergence 2024

    Adalimumab Biosimilar-to-biosimilar Switch in Patients with Inflammatory Rheumatic Diseases – Real-world Evidence from the Nationwide Danish Registry, DANBIO

    Kasper Yde Jensen1, Hafsah Nabi2, Dorte Vendelbo Jensen3, Jens Pedersen4, Oliver Hendricks5, Anne Gitte Loft6, Ada Colic7, Kamilla Danebod3, Salome Kristensen8, Heidi Munk9, Niels Lomborg10, Natalia Manilo11, Stavros Chrysidis12, Søren Just13, Asta Linauskas14, Pil Højgaard15, Pia Høger Thygesen16, Malene Kildemand17, Rene Drage Oestgaard18, Merete Hetland19 and Bente Glintborg20, 1Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark, 2DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Copenhagen, Denmark, Glostrup, Denmark, 3Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Glostrup, Denmark, 4Department of Rheumatology C, Research Unit, Odense University Hospital and Department of Clinical Research, University of Southern Denmark, Odense, Denmark, 5Danish Hospital For Rheumatic Diseases, Sønderborg, Denmark, 6Department of Rheumatology, Aarhus University Hospital and Aarhus University, Aarhus, Denmark, 7Department of Rheumatology, Zealand University Hospital, Koege, Denmark, 8Centre of Rheumatic Research Aalborg, Department of Rheumatology and Aalborg University Hospital and Department of Clinical Medicine, Aalborg University, Aalborg, Denmark, 9Department of Rheumatology, Odense University Hospital, Odense, Denmark and Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, 10Department of Rheumatology, Vejle Hospital Lillebælt, Odense C, Denmark, 11Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Denmark, 12Department of Rheumatology, University Hospital of Southern Denmark, Esbjerg, Denmark, 13Medicinsk Afdeling Svendborg Sygehus OUH, Odense, Denmark, 14Department of Rheumatology, North Denmark Regional Hospital, Hjoerring, Denmark and Department of Clinical Medicine, Aalborg University, Aalborg, Denmark, 15Department of Internal Medicine 2; Rheumatology, Holbæk Sygehus, Holbæk, Denmark and Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Frederiksberg Hospital, Copenhagen, Denmark, 16Department of Rheumatology, Slagelse Hospital, Slagelse, Denmark, 17Department of Rheumatology, Odense University Hospital, Svendborg, Denmark, 18Department of Medicine, Goedstrup Regional Hospital and Diagnostic Center, Silkeborg Regional Hospital, Silkeborg, Denmark, 19DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark, Glostrup, Denmark, 20DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark

    Background/Purpose: In Denmark, mandatory switches between originators and corresponding biosimilar products have been performed for economic reasons for nearly a decade (1). Starting in January…
  • Abstract Number: 1874 • ACR Convergence 2024

    Validation Analysis of the Expanded Risk Score for Rheumatoid Arthritis in a Multicentre Italian Cohort

    Fabio Cacciapaglia1, Gian Luca Erre2, Matteo Piga3, Elena Bartoloni Bocci4, Andreina Manfredi5, Ennio Giulio Favalli6, Maria Sole Chimenti7, Serena Guiducci8, Eleonora Celletti9, Addolorata Corrado10, Alessandro Giollo11, SIMONE PARISI12, Ivan Giovannini13, Elisa Gremese14, Francesca Romana Spinelli15, Garifallia Sakellariou16, Ombretta Viapiana17 and Fabiola Atzeni18, and Cardiovascular Obesity and Rheumatic DISeases Study Group of the Italian Society of Rheumatology, 1Rheumatology Unit DiMePRe-J, University and AOU Policlinico of Bari, Italy, Bari, Italy, 2Rheumatology Unit - University of Sassari, Sassari, Italy, 3Rheumatology Unit - Department of Medical Sciences and Public Health, University of Cagliari, Monserrato, Italy, 4Rheumatology Unit. Department of Medicine, Perugia, Perugia, Italy, 5University of Modena and Reggio Emilia, Modena, 6ASST Gaetano Pini-CTO, Milan, Lombardia, Italy, 7Rheumatology, Allergology and Clinical Immunology, University of Rome Tor Vergata, Roma, Italy, 8University of Florence, Pistoia, Italy, 9Medical Clinic, SS. Annunziata Hospital of Chieti, Department of Medicine and Science of Aging, G. D'Annunzio University of Chieti-Pescara, Chieti, Italy, 10Rheumatology Unit, University of Foggia, Foggia, Italy, 11Azienda Ospedale Università Padova, Padova, Padua, Italy, 12Rheumatology Unit, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, TURIN, Italy, 13Azienda Sanitaria Universitaria Friuli Centrale, Udine, Udine, Italy, 14Catholic University of the Sacred Heart, Rome, Rome, Italy, 15Sapienza University of Rome, Rome - Italy, Roma, Rome, Italy, 16Department of Internal Medicine and Medical Therapy, University of Pavia, and Istituti Clinici Scientifici Maugeri IRCCS Pavia,, Pavia, Italy, 17Rheumatology Unit, University of Verona, Verona, Italy, 18University of Messina, Italy, Messina, Italy

    Background/Purpose: This study aimed to compare the performance of three validated algorithms for 10-year global cardiovascular risk stratification (GCVR): the European Systemic Coronary Risk (SCORE-2)…
  • Abstract Number: 2492 • ACR Convergence 2024

    ANCA Associated Tracheobronchial Disease

    Megan Sullivan1, Maximiliano Diaz Menindez2, Ronald Butendieck3, hassan baig4, Anushka Irani5, Benjamin Wang3, Florentina Berianu5, Carolyn Mead-Harvey6, Andy Abril5 and Vikas Majithia4, 1Mayo Clinic Arizona, Scottsdale, AZ, 2Mayo Clinic School of Graduate Medical Education, Phoenix, AZ, 3Mayo Clinic, Jacksonville, FL, 4Mayo Clinic Florida, Jacksonville, FL, 5Mayo Clinic, Ponte Vedra Beach, FL, 6Mayo Clinic, Scottsdale, AZ

    Background/Purpose: Tracheobronchial disease is a common manifestation of ANCA associated vasculitis (AAV). However, outcomes data is commonly unreported in prospective studies. We performed a retrospective…
  • Abstract Number: 0306 • ACR Convergence 2024

    Cardiovascular Risk Estimated with the New PREVENT Calculator and Disease Activity in Patients with Rheumatoid and Psoriatic Arthritis

    Aleydis Gonzalez Melendez1, Rebeca L. Polina-Lugo1, Maria F. Elizondo-Benitez2, Andrea Guajardo Aldaco1, Osvaldo Uresti3, Ricardo I. de la Rosa-Vazquez3, Iris Jazmín Colunga Pedraza1, Dionicio Galarza-Delgado4, jose Ramon Azpiri-Lopez5, Rosa Icela Arvizu-Rivera1 and Jesus Cardenas-de la Garza6, 1Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 2Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, 3Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, 4UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, 5Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 6Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico

    Background/Purpose: The American Heart Association's PREVENT (Predicting Risk of Cardiovascular Disease EVENTs) is a new calculator developed in 2024, which estimates the 10- and 30-year…
  • Abstract Number: 1133 • ACR Convergence 2024

    Relationship Between Nail Psoriasis Severity Index (NAPSI) and Cardiovascular Risk Assessed by Eight Cardiovascular Risk Calculators

    Maria F. Elizondo-Benitez1, Iris Jazmín Colunga Pedraza2, jose Ramon Azpiri-Lopez3, Dionicio Galarza-Delgado4, Jesus Cardenas-de la Garza5, Rosa Icela Arvizu-Rivera2, Andrea Guajardo Aldaco2 and Valeria Gonzalez-Gonzalez6, 1Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, 2Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 3Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 4UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, 5Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, 6Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico

    Background/Purpose: Psoriatic arthritis (PsA) is a chronic, inflammatory, and immune-mediated disease that affects up to 30% of psoriasis (PsO) patients. Nail psoriasis affects 80% of…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology